In the 2nd quarter of 2010, the net profit of the American pharmaceutical company Allergan increased by 36% and amounted to 240 million US dollars. Pharmaceutical sales increased 10%, driven in part by higher sales of Botox anti-wrinkle product. A drug recently approved in the UK to prevent chronic migraines is up 7% to $361 million. The company also said the FDA has extended its review period for the drug for these indications, although analysts tend to be positive.